NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $22.49 (+2.55%), Market cap $4.31B, 52-week low–high $17.01 ~ $41.45.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Financial statements, price targets, institutional (13F) holdings and related news for NewAmsterdam Pharma Company N.V. Ordinary Shares are updated in real time on BlackAll Trade.
NewAmsterdam Pharma Company N.V. Ordinary Shares trades at $22.49 (+2.55%). Real-time quotes and charts are available on BlackAll Trade.
NewAmsterdam Pharma Company N.V. Ordinary Shares has a market cap of about $4.31B.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral